Cell engineering

Phytolon and Ginkgo Bioworks Successfully Achieve First Milestone to Produce Vibrant Natural Food Colors via Two Producing Strains

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Cell engineering, Senior, DNA, Food, Biotechnology, Commercialization, Food industry

Ginkgo and Phytolon's partnership, which began in February 2022, aims to produce vibrant betalain pigments spanning the entire yellow-to-purple spectrum using cell engineering.

Key Points: 
  • Ginkgo and Phytolon's partnership, which began in February 2022, aims to produce vibrant betalain pigments spanning the entire yellow-to-purple spectrum using cell engineering.
  • By leveraging Ginkgo Natural Product Services , Phytolon has significantly improved the efficiency of its yeast strains to generate these vibrant, sustainable colors and offer cost-efficient replacements to artificial dyes.
  • By partnering with Ginkgo, Phytolon is in a strong position to scale their robust array of food colorants for the global market.
  • Ginkgo and Phytolon will continue to work together under their existing agreement toward achieving additional milestones that further increase production efficiency.

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Retrieved on: 
Tuesday, January 23, 2024
ASX, Neoplasm, Patient, Precision, Partnership, Imugene, Cancer, Workflow, GMP, CD19, IMU, Cell engineering, SPL, Bone marrow, Transfection, Immune system, Pharmaceutical industry

Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
  • Imugene, which has offices in the United States and Australia, is focused on developing transformative cancer medicines to improve patients’ lives.
  • Imugene is MaxCyte’s 25th SPL overall, which generates pre-commercial milestone revenue, the vast majority of which includes post-commercial revenue.

Alaya.bio announces significant collaboration with leading global cancer center to advance in situ CAR-T Therapy

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, Pharmaceutical, Health, Patient, Nanoparticle, Cell engineering, Research, CSO, Bone marrow, MSK, Doctor of Philosophy, Cell, Messenger, Gene editing, Pharmaceutical industry

The collaboration will advance research into in situ CAR-T cell therapies and evaluate their potential to deliver faster, more effective, and cost-efficient treatments for patients.

Key Points: 
  • The collaboration will advance research into in situ CAR-T cell therapies and evaluate their potential to deliver faster, more effective, and cost-efficient treatments for patients.
  • The collaboration with the Sadelain lab includes a license agreement and a sponsored research agreement.
  • Over the coming two years the Sadelain lab will lead activities to advance Alaya.bio’s polymeric delivery platform into the clinic in a chosen hematological malignancy.
  • This innovative approach guarantees stable expression of the CAR transgene and preserves transduced T-cells from exhaustion, two crucial features for long-term clinical benefit.

SOHM Files Provisional Patent on ABBIE’s ‘Smart Gene-Editing’ That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations

Retrieved on: 
Tuesday, January 9, 2024
Nanoparticle, Health, DNA, Agriculture, Graphene, Medicine, Communication, Risk, Safety, Cell engineering, FDA, Genome, Point-of-care testing, Cell, Vaccine

SOHM’s developers have recently submitted a provisional patent application detailing technology designed to more tightly control editing events.

Key Points: 
  • SOHM’s developers have recently submitted a provisional patent application detailing technology designed to more tightly control editing events.
  • This patent pending ABBIE technology will leverage effector molecules, such as kinases and phosphatases, to regulate the activity of engineered DNA at a target site.
  • ABBIE will also utilize advances in graphene-based nanomaterials, nano sensors, and wireless communication technologies allowing for enhanced control and fine-tuning of the gene editing process.
  • SOHM has filed a provisional patent application on its innovative technology.

Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 10, 2024
Cloud, DNA, Partnership, Novo Nordisk, Biogen, AI, Pfizer, Conference, Cell engineering, Pressure, Ginkgo, Boehringer Ingelheim, Google Cloud, Merck, Growth

BOSTON, Jan. 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced preliminary performance updates for the year ended December 31, 2023. Among the results, Ginkgo highlighted that it expects to meet its previously disclosed new program and revenue guidance ranges in 2023 based on its preliminary unaudited estimates. A business review, including a discussion of Ginkgo's platform services for large scale data generation and AI to enable biopharma R&D, will be featured in a presentation today at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • ET)
    BOSTON, Jan. 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced preliminary performance updates for the year ended December 31, 2023.
  • Among the results, Ginkgo highlighted that it expects to meet its previously disclosed new program and revenue guidance ranges in 2023 based on its preliminary unaudited estimates.
  • A business review, including a discussion of Ginkgo's platform services for large scale data generation and AI to enable biopharma R&D, will be featured in a presentation today at the 42nd Annual J.P. Morgan Healthcare Conference.
  • J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
    As previously announced, co-founder and CEO Jason Kelly is scheduled to participate in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT (12:45 p.m.

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

Retrieved on: 
Wednesday, January 3, 2024
SPL, Hepatitis B virus, Partnership, Hepatocellular carcinoma, Immune system, Research, TCR, Lion, HBV, Cell engineering, MBA, Laboratory, Viral, Cancer, Patient, Safety, Therapy, Vaccine

This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets.

Key Points: 
  • This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets.
  • Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • “We are thrilled to partner with Lion TCR to support the development of their TCR-T cell therapies for hepatocellular carcinoma and life-threatening viral infections,” said Maher Masoud, President and CEO of MaxCyte.
  • Lion TCR is MaxCyte’s 24th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.

Global and Regional Cultured Meat Ingredients Market Analysis and Forecast Report 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 20, 2023
Science, Other Science, Agriculture, Natural Resources, Other Manufacturing, Food, Beverage, Manufacturing, Retail, Meat, Growth, Food industry, Safety, Cell engineering, Nutrient, Education, Bioreactor, Livestock, Environment

The "Cultured Meat Ingredients Market - A Regional and Global Analysis - Analysis and Forecast, 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cultured Meat Ingredients Market - A Regional and Global Analysis - Analysis and Forecast, 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Cultured Meat Ingredients Market is experiencing a transformative shift in the food industry, as an increasing number of consumers and food companies seek sustainable and alternative protein sources.
  • This report provides a comprehensive analysis of the Cultured Meat Ingredients Market, focusing on alternate protein sources, cell engineering techniques, and the barriers in the commercialisation of cultivated meat.
  • Cultivated meat, also known as cell-based meat or lab-grown meat, represents a pioneering development in the food industry.

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

Retrieved on: 
Wednesday, December 6, 2023
Research, Surgery, Hospitals, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Harold Fowler McCormick, GMP, Hope, Therapy, Northwestern University, CDMO, Transplant, Patient, Multimedia, FDA, Autoimmune disease, Cell engineering, Medical College of Wisconsin, Organ transplantation, MD, CGMP, Partnership, Doctor of Philosophy, Medical college, Phase II, Quality of life, Pharmaceutical industry

Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.

Key Points: 
  • Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.
  • View the full release here: https://www.businesswire.com/news/home/20231206255985/en/
    This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modulating regulatory T cell therapy platform.
  • "We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options," said Cyrus Yang, COO of Taiwan Bio.
  • Our Phase 2 trial represents a significant step forward in our mission to provide solid organ transplant patients with better treatment options."

SES to Host Battery World 2023 and Announce World’s First Automotive B-sample JDA for Li-Metal

Retrieved on: 
Monday, November 13, 2023
Hardware, Alternative Energy, Energy, Manufacturing, Technology, Transportation, Other Automotive, EV, Electric Vehicles, Travel, Other Transport, Trucking, Transport, Other Technology, Automotive, Other Energy, Engineering, Cell engineering, EVS, SES, NYSE, Multimedia, JDA, Newton (unit), Medical device, Boston

SES AI Corporation (NYSE: SES) ("SES AI" or "SES"), headquartered in Boston, a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced that it will host its 3rd annual Battery World on December 12, 2023.

Key Points: 
  • SES AI Corporation (NYSE: SES) ("SES AI" or "SES"), headquartered in Boston, a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced that it will host its 3rd annual Battery World on December 12, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231113176893/en/
    During Battery World 2023, SES AI anticipates announcing several exciting new developments, including:
    In addition to the aforementioned topics, SES AI expects to detail many other exciting initiatives.
  • “Battery World 2023 will be our most exciting event since our inaugural Battery World in 2021 when we first demonstrated our large capacity Li-Metal automotive cells that had energy density of ~400 Wh/Kg .
  • At that time, we became the world’s first Li-Metal cell manufacturer to enter into an automotive A-sample JDA.

Foremost Farms Selects Ginkgo Bioworks to Develop Technology for Upcycling Dairy Co-products

Retrieved on: 
Thursday, November 9, 2023
Cell engineering, NYSE, Biotechnology, Farm, Cheese, Metabolic engineering, Carbon, Ginkgo, Carbon footprint, Environment, Biology, Foremost, Commercial, Partnership, Farmer, Butter, D, DNA, Dairy, Agriculture

Through this partnership, Foremost Farms will leverage Ginkgo's bioproduction services to develop and commercialize a new technology that could help upcycle billions of pounds of dairy co-products each year.

Key Points: 
  • Through this partnership, Foremost Farms will leverage Ginkgo's bioproduction services to develop and commercialize a new technology that could help upcycle billions of pounds of dairy co-products each year.
  • Foremost Farms has selected Ginkgo as its partner of choice to develop a new upcycling technology because of Ginkgo's leading metabolic engineering and analytical capabilities, which will allow strain optimization for challenging environmental conditions while avoiding common toxicity issues.
  • Ginkgo aims to help Foremost build a technology to reduce this carbon footprint by upcycling these low-value co-products.
  • "We're excited to partner with Ginkgo Bioworks, which can uniquely help Foremost Farms realize its goals.